Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New paradigms for treatment development.

Ellen L Stover1, Linda Brady, Stephen R Marder

  • 1National Institute of Mental Health, Bethesda, MD, USA.

Schizophrenia Bulletin
|August 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.

Schizophrenia bulletin open·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

Schizophrenia bulletin open·2026
Same author

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Schizophrenia research·2026
Same author

Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures?

The American journal of psychiatry·2026
Same author

Rethinking Antipsychotic Comparisons: The Role of Prior Exposure and Tolerability.

The American journal of psychiatry·2026

The National Institute of Mental Health (NIMH) can accelerate drug development for public health issues. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative exemplifies this new paradigm for schizophrenia treatment.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • The National Institute of Mental Health (NIMH) has a crucial role in addressing public health challenges where existing treatment development is insufficient.
  • Past successes in HIV/AIDS research demonstrated the NIMH's capacity to expedite new research in critical areas.
  • Wayne Fenton advocated for governmental intervention, particularly by the NIMH, to tackle significant public health problems.

Discussion:

  • This report details how Fenton and colleagues united industry, government, and academic sectors to advance drug development.
  • Key areas addressed included novel preclinical approaches and the identification of new therapeutic targets for schizophrenia.
  • The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative serves as a case study for innovative treatment development.

Related Experiment Videos

Key Insights:

  • The NIMH can effectively facilitate rapid development of new research in critical public health areas.
  • Collaborative efforts between industry, government, and academia are vital for addressing complex health issues.
  • The MATRICS initiative represents a successful model for developing novel pharmacological treatments for cognitive impairments in schizophrenia.

Outlook:

  • This collaborative model can be applied to other public health challenges requiring accelerated treatment development.
  • Further research into preclinical approaches and therapeutic targets is essential for advancing schizophrenia treatment.
  • Continued investment in public-private partnerships can drive innovation in mental health treatment development.